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ABSTRACT
The frequency distribution of mutation-induced
aberrant 30 splice sites (30ss) in exons and introns
is more complex than for 50 splice sites, largely
owing to sequence constraints upstream of intron/
exon boundaries. As a result, prediction of their
localization remains a challenging task. Here, nuc-
leotide sequences of previously reported 218 aber-
rant 30ss activated by disease-causing mutations in
131 human genes were compared with their authen-
tic counterparts using currently available splice
site prediction tools. Each tested algorithm distin-
guished authentic 30ss from cryptic sites more
effectively than from de novo sites. The best dis-
crimination between aberrant and authentic 30ss
was achieved by the maximum entropy model.
Almost one half of aberrant 30ss was activated
by AG-creating mutations and  95% of the newly
created AGs were selected in vivo. The overall nuc-
leotide structure upstream of aberrant 30ss was
characterized by higher purine content than for
authentic sites, particularly in position  3, that may
be compensated by more stringent requirements for
positive and negative nucleotide signatures centred
around position  11. A newly developed online
database of aberrant 30ss will facilitate identifica-
tion of splicing mutations in a gene or phenotype
of interest and future optimization of splice site
prediction tools.
INTRODUCTION
Mutations that affect pre-mRNA splicing have been shown to
account for up to a half of disease-causing gene alterations
(1,2), potentially representing the most frequent cause of
hereditary disorders (3). The most common consequence
of splicing mutations is skipping of one or more exons, fol-
lowed by the activation of aberrant 50 (donor) splice sites
(50ss), 30 (acceptor) splice sites (30ss) and retention of full
introns in mRNA (4,5). Each of these four events may have
a dramatic impact on the structure or outcome of mature tran-
scripts, function of their translation products and phenotypic
manifestations. However, gene mutations or variants can also
have more subtle effects at the level of splicing by altering
the expression of pre-existing alternatively spliced mRNA
isoforms, which can considerably modify not only phenotypic
severity of both Mendelian and complex traits, but also their
population prevalence (6–9).
Mutation-induced aberrant splice sites have been classif-
ied into two categories (10): (i) cryptic splice sites, which
are only used when a mutation disrupts use of the authentic
site, and (ii) de novo splice sites, which are induced by muta-
tions elsewhere in introns or exons and increase the match to
a splice site consensus. However, distinction between the two
categories may be ambiguous in some cases since disruption
of the authentic site may create a new splice site consensus,
and is less obvious for 30ss than 50ss because accurate recog-
nition of acceptor sites requires additional signal sequences in
introns (11). The splicing signals of acceptor sites, namely the
branch point sequence (BPS), polypyrimidine tract (PPT),
and 30AG, are recognized by RNA–protein interactions
involving splicing factor 1 (SF1) and 65 and 35 kDa subunits
of the U2 small nuclear RNP auxiliary factor (U2AF65 and
U2AF35), respectively (12–17). The overall strength of 30ss
is deﬁned by optimal sequences for interaction with each cog-
nate factor as well as their distances from each other (18,19).
Cryptic 50ss have a similar frequency distribution in exons
and introns and their number decreases with an increasing
distance from authentic 50ss (10). In contrast, the localization
of cryptic 30ss is biased towards exons, whereas de novo
30ss usually reside in introns, particularly within the PPT of
authentic 30ss (11). The distribution bias and a lower preval-
ence of aberrant 30ss than 50ss in vivo is most likely due to
sequence constraints near intron/exon boundaries, including
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BPS upstream of 30ss (11). In addition, the multifaceted dis-
tribution of aberrant 30ss would be predicted to reﬂect vari-
able distances between the 30ss signal sequence from intron
to intron (18–21), including the presence of putative ‘distant
BPS’ that are not located within an optimal distance of 18–
40 nt 50 of 30ss, but may reside up to several hundred nucle-
otides further upstream (22). Despite a growing number of
reported splicing mutations and associated phenotypes, the
localization of the resulting aberrant 30ss and their effect on
gene expression remain difﬁcult to predict.
Currently available computational tools that estimate the
splice site strength have been based on a variety of methods,
including nucleotide frequency matrices (23,24), machine
learning approaches (25), neural networks (26), informa-
tion theory (27) and interdependence between adjacent (the
ﬁrst-order Markov model) or more distant (the maximum
entropy model) positions of the splicing consensus sequences
(28). Gene prediction algorithms that take into account pro-
tein coding information have been shown to perform better
than those that rely only on signals present in the splice
sites (29). However, the strength of mutation-induced
aberrant splice acceptor sites has not been systematically ana-
lyzed, and it is unknown at present which models best
predict the localization of cryptic or de novo 30ss activated
in vivo.
Here, nucleotide sequences of aberrant 30ss that were
reported previously in human disease genes have been com-
piled and made available to the public through an online
retrieval tool. Comparison of the splice site strength using
current prediction algorithms showed that the maximum
entropy model allowed the best discrimination between
authentic and mutation-induced aberrant 30ss, validating this
model as the most sensitive instrument. In addition, this
study provides a detailed characterization of the underlying
mutation pattern and comparison of nucleotide composition
upstream of aberrant and corresponding authentic 30ss.
MATERIALS AND METHODS
Compilation of mutation-induced aberrant 30ss in
human disease genes
Published reports of cryptic and de novo 30ss were identiﬁed
by searching PubMed (http://www.ncbi.nlm.nih.gov/entrez/
query.fcgi) and home pages of peer-reviewed journals. A sub-
set of case reports were identiﬁed by searching locus-speciﬁc
mutation databases (http://archive.uwcm.ac.uk/uwcm/mg/
docs/oth_mut.html). The search was restricted to human
genes with sequence-veriﬁed aberrant RNA products pub-
lished before May 2006 that resulted from disease-associated
mutations or variants. Nine cases in which no patient RNA
was available but aberrant RNA products of wild-type and
mutated alleles were characterized in minigene splicing
reporter assays were also included. Aberrant 30ss were manu-
ally validated by mapping the information in the literature to
sequences in the Human Genome Project databases. Nucle-
otide sequences of authentic, mutated and aberrant 30ss are
available at http://www.dbass3.soton.ac.uk/ in the ﬁrst online
database of aberrant 30ss termed DBASS3.
Comparison of computational methods to predict
aberrant 30ss
Validated sequences of aberrant and corresponding authentic
30ss were used as input ﬁles for several splice site prediction
algorithms. The Shapiro and Senapathy (S&S) matrix is
based on nucleotide frequencies at each position of the 30ss
consensus sequence (23,24). The S&S matrix scores were
computed using an online tool available at http://ast.bioinfo.
tau.ac.il/. The information theory-based server (27) available
at https://splice.cmh.edu/ was used to obtain the information
content (Ri) of 30ss in bits. To accommodate dependencies
between adjacent and non-adjacent positions, the compiled
sequences were analyzed using the ﬁrst-order Markov
(MM) and the maximum entropy (ME) models (28). The
former method considers dependencies between adjacent
positions, whereas the latter approximates short sequence
motif distributions with the ME distribution and may include
dependencies between non-adjacent as well as adjacent
positions. The MM and ME scores (28) were derived for
each 30ss using online tools available at http://genes.mit.
edu/burgelab/maxent/Xmaxentscan_scoreseq_acc.html. The
Wilcoxon Mann–Whitney rank test (Stat-200, v. 2.01, Bio-
soft, UK) was employed to test the signiﬁcance of score
differences between authentic, mutated and aberrant 30ss in
each category.
DBASS3 construction
DBASS3 is an online retrieval and submission tool for
mutation-induced aberrant 30ss available at http://www.
dbass3.soton.ac.uk/. The web application was created using
the ASP server technology (Microsoft), and SQL database
software (http://www.sql.org). In addition to aberrant 30ss
induced by germ-line and somatic mutations, DBASS3
contains naturally occurring variants common in the popula-
tion if they have been convincingly shown to modify both
alternative pre-mRNA splicing and disease phenotypes,
such as FECH IVS3-48T/C in protoporphyria (8). Genetic
polymorphisms that may inﬂuence utilization of tandemly
arranged ‘NAGNAG’ 30ss (30) and exert putative functional
effects have been reported elsewhere (31) and were not
included in DBASS3, nor were the mutations leading to
exon skipping or complete intron retention.
RESULTS
Mutations that activate aberrant 30ss
An exhaustive search for previously published aberrant 30ss
identiﬁed 218 unique aberrant acceptors in 131 genes
(Table 1). They were generated by a total of 16 deletions/
insertions (32–46) and 211 point mutations (Table 2). Single-
nucleotide substitutions of purine residues were much more
frequent than those of pyrimidines (165 versus 46, P <
10
 16). This overrepresentation was not attributable solely
to substitutions at 30YAG (102 versus 8), but was also
observed for de novo 30ss (63 versus 38, P ¼ 0.004). The
most frequently introduced base in each of the four categories
of aberrant 30ss was guanine (G), accounting for  42%
(89/211) of all point mutations (Table 2).
Nucleic Acids Research, 2006, Vol. 34, No. 16 4631As expected, point mutations were most common in highly
conserved positions  1 (53/211; 25%) and  2 (48/211; 23%)
relative to natural intron/exon junctions (Table 3). Position
 3 was mutated in nine cases ( 4%). As noted in the initial
analysis of all splice site mutations for position  2 (47), G-
to-Y (in position  1; Y is pyrimidine) and A-to-Y (position
 2) transversions were under-represented as compared with
G-to-A and A-to-G transitions, respectively (P < 0.01 and
P < 0.00001, assuming that substitutions to the remaining
nucleotides were equally probable; Table 3). Since transitions
are in signiﬁcant excess in humans compared with the exp-
ected frequency of 33% (47), the expected numbers were
calculated for each substitution using previously published
single-nucleotide mutability rates in disease genes (Table 3).
However, the observed number of G 1-to-T 1 mutations
was too low to be explained by chance, suggesting that
primary transcripts carrying the A 2T 1 acceptors generate
on average more canonical mRNAs as compared with
30AG mutated to other dinucleotides, leading to a detec-
tion bias against less severe phenotypes. This notion is sup-
ported by similar frequencies of G>T/C>A and G>C/C>T
alterations among disease-causing point mutations (48)
and by the presence of residual amounts of natural transcripts
Table 2. Summary of mutations leading to aberrant 30ss
Location of cryptic or de novo 30ss
Exon Intron Both
Mutation in
30YAG (cryptic)
Mutation outside
30YAG (‘de novo’)
Mutation in
30YAG (cryptic)
Mutation outside
30YAG (‘de novo’)
All mutations
Number of deletions/insertions 7 3 0 6 16
Number of single-nucleotide substitutions 81 29 29 72 211
Wild-type nucleotide
A 36 3 13 29 81
C2 9 5 9 2 5
G4 3 1 3 1 0 1 8 8 4
T 0 4 1 16 21
Mutated nucleotide
A2 3 8 5 2 8 6 4
C2 1 3 5 2 3 1
G 25 9 14 41 89
T1 2 9 5 1 2 7
Number of AG-creating mutations
Total number (%) 16 (7) 12 (5) 8 (4) 62 (27) 98 (43)
Not used as aberrant 30ss (%) 0 5 2 4 11 (5)
Table 1. Summary of aberrant 30ss
Location of cryptic or de novo 30ss
Exon Intron Both
Mutation in
30YAG (cryptic)
Mutation outside
30YAG (‘de novo’)
Mutation in
30YAG (cryptic)
Mutation outside
30YAG (‘de novo’)
All
mutations
Number of genes 54 25 23 56 131
Number of cryptic and de novo 30 ss (per cent) 88 (39) 32 (14) 29 (13) 78 (34) 227 (100)
Number of unique 30ss (per cent) 83 (38) 29 (13) 28 (13) 78 (36) 218 (100)
Number of aberrant 30ss affecting terminal exons (per cent) 11 (13) 4 (14) 8 (29) 4 (5) 27 (12)
Median distance (nucleotide) between
authentic and aberrant 30ss
12 55  44  14 1
Change in the reading frame for unique aberrant 30ss
0 29 10 8 27 74
+1 38 7 13 26 84
+2 21 15 8 25 69
Table 3. Number of single-nucleotide substitutions in 30YAG that resulted in
cryptic 30ss
Observed Expected
Location of cryptic 30 splice site Exon Intron Both Mono-
a Di-
b
Point mutations in position IVS-1 43 10 53 — —
 1G>A 23 4 27 25.2
c 31.5
d
 1G>C 14 3 17 10.9 13.2
 1G>T 6 3 9 16.9 8.3
Point mutations in position IVS-2 36 12 48 — —
 2A>C 7 2 9 9.3
e 8.8
f
 2A>G 23 8 31 30.6 35.5
 2A>T 6 2 8 8.1 3.7
Point mutations in position IVS-3 2 7 9 — —
 3C>N2 5 7 — —
 3T>N0 1 1 — —
 3A>N0 1 1 — —
Expectednumbers of both exonic and introniccryptic 30ss were calculated as a
weighted average of relative mono-
a (47) and di-
b (48) nucleotide mutability
ratesinthesenseandantisenseDNAstrandsthatwerepublishedpreviouslyfor
a large number of point mutations in human disease genes. Relative substitu-
tion rates at the di-nucleotide level allow for the nearest-neighbour effects as
previously described (48).
cc
2¼6.2, P ¼ 0.046,
dc
2¼1.3, P > 0.05,
ec
2¼0.02,
P > 0.05;
fc
2¼4.4, P > 0.05.
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cerevisiae (49) and humans (50). However, comparison
of the observed and expected distributions derived from
di-nucleotide mutability rates that allow for the inﬂuence
of neighbouring nucleotides (48) failed to conﬁrm any
bias for both intron positions (Table 3). Thus, although
small effects of ‘leaky’ dinucleotides on the observed
distribution cannot be excluded, these data are consistent
with dramatic consequences for splicing of any point
mutation in the highly conserved 30AG and with indistin-
guishable defects of the second splicing step previously
observed in vitro both for intron position  1 (51) and
 2 (52).
Interestingly, as many as 14/53 (26%) point mutations in
position  1 (IVS-1G>A if the ﬁrst exon nucleotide was G)
(34,53–64), 3/48 (6%) substitutions in position  2 (IVS-
2A>G) (65,66) and 2/9 (22%) point mutations in position
 3 [IVS-3T>G (67) and IVS-3A>G (68)] created new
30AG sites that were used in vivo (Figure 1). The proportion
of AG-creating mutations in position  1 was higher than
in position  2( P ¼ 0.01, Fisher’s exact test), which may
have contributed to the higher number of substitutions
observed in position  1 than  2 (Table 3). In contrast to
mutations in the 30YAG consensus, the majority of substitu-
tions in the PPT were AG-creating mutations. For example, in
positions  5t o 26 relative to natural intron/exon junctions
as many as 61/73 (84%) point mutations mutations created
new AGs (Figure 1). The overall proportion of AG-creating
mutations that resulted in aberrant 30ss was 43%, and
 95% of the newly introduced 30AGs were used in vivo
(Table 2).
Purine transitions, which accounted for  54% (113/211) of
all aberrant 30ss and dominated the mutation pattern of cryp-
tic 30ss, were also the most frequent point mutations leading
to de novo 30ss (54/101; 53%). De novo sites in introns resul-
ted from purine transitions more often than de novo sites
in exons (45/72 versus 9/29, c
2 ¼ 7.0, P ¼ 0.008). Intronic
de novo 30ss were most frequently induced by substitutions
of A (29/72, 40%), whereas exonic de novo 30ss were most
commonly activated by point mutations of G (13/29, 45%;
Table 2).
Comparison of computational tools to predict
mutation-induced aberrant 30ss in vivo
The predicted strength of aberrant, mutated and correspond-
ing authentic 30ss was analyzed using publicly available
computational tools shown in Table 4. Each of the tested
models distinguished authentic, mutated and aberrant 30ss,
with authentic sites giving, on average, the highest scores
or information bits, followed by aberrant and then by mutated
30ss (Table 5). However, this was not the case for each
category of aberrant acceptors.
First, each computational tool was more effective in dis-
criminating authentic and aberrant 30ss that resulted from
mutations in the 30YAG consensus than from mutations else-
where (Table 5). This was owing to signiﬁcantly higher
scores for authentic 30ss that corresponded to cryptic 30ss
than for authentic counterparts of de novo sites. For example,
the S&S scores for authentic counterparts of de novo and
cryptic 30ss were 80.5 ± 8.4 (±SD) and 84.6 ± 6.4 (P <
10
 7, Wilcoxon Mann–Whitney rank test), respectively. Sim-
ilarly, the ME scores were 7.2 ± 3.2 and 8.6 ± 3.3, respect-
ively (P < 10
 7). In contrast, the score differences between
cryptic and de novo 30ss were not statistically signiﬁcant
(means of the S&S matrix scores were 76.5 versus 77.7,
P ¼ 0.3; means of the ME scores were 4.7 versus 5.3,
P ¼ 0.4, respectively). Scores or information bits for each
category of aberrant acceptors are shown in Table 4. These
results indicate that authentic counterparts of de novo 30ss
are intrinsically weak and can be outcompeted by newly cre-
ated splicing consensus elements. They also suggest that
mutations or genetic variants ﬂanking weak splice sites are
more likely to play a role in regulated splicing than those
near well-deﬁned sites, consistent with weakening of splicing
signals in evolution from virtually invariable sequences in
yeasts to highly degenerate in humans and a need for more
sophisticated regulation in complex organisms at the level
of alternative splicing.
Second, each algorithm could distinguish cryptic and
authentic 30ss in exons, whereas matrix-based scores
struggled to differentiate between authentic and cryptic 30ss
in introns where the ME and MM were the only models
that showed P-values of 0.01 or lower (Table 5).
Figure 1. Frequency distribution of 184 intronic point mutations that activated aberrant 30ss
Nucleic Acids Research, 2006, Vol. 34, No. 16 4633Third, de novo 30ss could not be discriminated from
authentic sites by any algorithm if located in exons. Although
this could be partly attributed to a smaller sample size of
exonic than intronic de novo sites (Table 1), a similar sample
of intronic cryptic 30ss did show statistically signiﬁcant
differences for a subset of algorithms (Table 5). Finally, the
difference between intronic de novo sites and their authentic
counterparts was statistically signiﬁcant with the ME and
MM models but not with the remaining algorithms, except
for the S&S matrix scores.
Taken together, these results indicated that the value of
computational tools to predict aberrant 30ss depended on
their localization in introns and exons as well as on the
underlying mutation, and that the ME was the best model dis-
criminating mutation-induced aberrant 30ss in vivo from cor-
responding authentic 30ss. They also suggested that the failure
to distinguish exonic de novo 30ss from authentic counterparts
may be due to our as yet incomplete understanding of the
role of exonic splicing silencers or enhancer elements in
30ss selection.
Single-nucleotide composition upstream of
aberrant 30ss
Comparison of the nucleotide structure upstream of aberrant
and authentic 30ss revealed a signiﬁcantly higher proportion
of purines in aberrant 30ss. For example, in intronic positions
 3 through  26 aberrant 30ss had 1760 purines as opposed
to 1526 purines in authentic 30ss (c
2 ¼ 23.7, P < 0.00001;
Supplementary Figure 1). Overall, this was attributable to a
higher number of As (c
2 ¼ 13.5, P < 0.001) rather than Gs
(c
2 ¼ 6.4, P ¼ 0.01; Supplementary Figure 1A). The increase
of purine residues was almost exclusively at the expense of
uridines for aberrant 30ss in exons (Supplementary
Figure 1B and C). In contrast, aberrant 30ss in introns showed
only a borderline increase of purine residues (c
2 ¼ 3.2, P ¼
0.07), largely owing to cytosine depletion (Supplementary
Figure 1D and E). De novo 30ss in exons had a smaller num-
ber of Gs as compared with authentic 30ss, but the difference
was not statistically signiﬁcant (Supplementary Figure 1C).
The increase of purines in aberrant 30ss was the highest
in position  3 where As were 6· more frequent than in
Table 4. Comparison of the strength of authentic, mutated and aberrant 30ss
Location of aberrant 30ss
Exon Intron Both
Mutation in
30YAG (cryptic)
Mutation outside
30YAG(‘denovo’)
Mutation in
30YAG (cryptic)
Mutation outside
30YAG(‘denovo’)
All mutations
Shapiro and Senapathy matrix score
A (SD) 84.5. (6.5) 79.3 (9.8) 85.0 (6.1) 81.0 (7.8) 82.6 (7.7)
M (SD) 67.5 (8.0) 78.9 (9.4) 70.2 (6.6) 79.4 (8.7) 73.5 (10.0)
CR (SD) 74.5 (9.2) 78.6 (10.4) 82.7 (8.5) 77.3 (9.0) 77.1 (9.5)
A–M 17.1 0.5 14.8 1.6 9.2
M–CR 7.1  0.3 12.4  2.1 3.6
A–CR 10.0 0.7 2.4 3.6 5.5
Maximum entropy model
A (SD) 8.7 (3.5) 6.7 (4.0) 8.6 (3.0) 7.3 (2.9) 7.9 (3.4)
M (SD)  0.3 (4.5) 5.8 (5.1)  0.4 (3.6) 3.8 (4.1) 2.0 (5.0)
CR (SD) 4.1 (3.9) 5.5 (5.6) 6.4 (3.6) 5.2 (4.5) 5.0 (4.4)
A–M 8.4 0.5 9.0 3.2 5.6
M–CR 4.1  0.4 6.8 1.8 3.0
A–CR 4.4 0.9 2.2 1.4 2.6
First-order Markov model
A (SD) 9.1 (3.0) 7.1 (4.1) 8.9 (2.8) 7.5 (3.0) 8.2 (3.2)
M (SD) 0.1 (3.9) 6.2 (5.1) 0.3 (3.0) 4.0 (4.1) 2.3 (4.7)
CR (SD) 4.4 (3.9) 5.3 (5.9) 7.1 (3.2) 5.4 (4.8) 5.2 (4.6)
A–M 8.9 0.8 8.5 3.5 5.9
M–CR 4.3  0.9 6.7 1.4 2.9
A–CR 4.7 1.7 1.8 2.1 3.0
Weight matrix model
A (SD) 9.9 (3.8) 7.3 (4.3) 9.6 (3.0) 7.5 (4.1) 8.7 (4.0)
M (SD) 1.1 (4.3) 7.1 (4.2) 1.4 (3.1) 6.6 (4.0) 3.9 (4.9)
CR (SD) 4.6 (4.8) 6.2 (5.3) 8.1 (3.5) 6.2 (4.8) 5.8 (4.8)
A–M 8.8 0.3 8.2 0.9 4.8
M–CR 3.6  0.9 6.8  0.4 2.0
A–CR 5.3 1.2 1.5 1.3 2.8
Information content
A (SD) 9.9 (3.9) 8.1 (3.9) 9.6 (3.1) 7.9 (3.9) 8.9 (3.9)
M (SD) 2.1 (3.8) 7.6 (3.8) 2.4 (3.3) 7.0 (3.7) 4.6 (4.5)
CR (SD) 5.9 (3.7) 7.2 (3.3) 8.0 (3.5) 7.5 (3.6) 6.9 (3.7)
A–M 7.8 0.5 7.2 0.8 4.3
M–CR 3.5  0.7 5.5 0.1 2.2
A–CR 4.1 1.0 1.7 0.7 2.2
MeansandSDofsplicepredictionscores(S&S,ME,MM,weightmatrixmodel)orbits(informationcontent)forauthentic(A),mutatedauthentic(M)andaberrant
(CR) 30ss. The length of input sequences was 15 ( 14 to +1 relative to authentic 30ss), 23 ( 20 to +3), 23 ( 20 to +3), 23 ( 20 to +3) and 28 ( 26 to +2) nt,
respectively.Theinformationcontentalgorithmfailedtorecognize7authentic,12mutatedand28aberrant30ssusedinvivo.Themissingvalues(47/654,7%)were
treated as a group mean.
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2 ¼ 26.5, P <
0.000001). The number of aberrant 30ss with G in position
 3 was also higher (7 versus 2) in aberrant (65,66,69–73)
than in corresponding authentic (70,74) 30ss. Positive associ-
ations between  3C and upstream Cs in the PPT and between
 3T and upstream Ts, which were described previously for
authentic 30ss (75), were observed also for aberrant 30ss (Sup-
plementary Table 2). Although the inﬂuence of  3C on the
relative usage of C versus T in the PPT may be attributed
to autocorrelation due to compositional similarities of local
genomic regions (75), sequence constraints resulting from
cooperative interactions at the 30ss could not be excluded.
Indeed, non-random distributions at  3 observed for posi-
tions  11,  12,  17 and  19 of aberrant 30ss (Supplement-
ary Table 2) may be explained by inefﬁcient binding of U2AF
to RNAs carrying 30TAG as compared to 30CAG (76) and a
need for functional compensation of the former by stronger
interaction of U2AF65 (or other PPT-binding proteins) with
uridines at positions  11 and  12 rather than cytosines.
Associations further upstream may involve similar compen-
sation by more optimal BPS interactions with the RS domain
of U2AF (77–79) and/or, possibly, other BPS-interacting fac-
tors, including K- and Quaking-homology 2 domains of SF1
(12,80,81) or U2 small nuclear RNA (82,83). Similar associ-
ations at  3 with upstream intron positions were seen also
for authentic counterparts of aberrant 30ss (data not shown),
conﬁrming previous ﬁndings with a larger dataset (75).
Although most of the analyzed positions upstream of aber-
rant 30ss showed uridine depletion as compared to authentic
sites (e.g. 565 versus 659 Ts in positions  5t o 10;
c
2 ¼ 12.8, P < 0.001; Supplementary Figure 2A), their num-
bers were similar further upstream between positions  11
and  13 (311 versus 319, P ¼ 0.7). Cs were slightly
under-represented between positions  11 and  13 in aber-
rant 30ss (168 versus. 202, c
2 ¼ 4.0, P ¼ 0.04). The T-to-C
ratio in aberrant 30ss was the highest in position  11 (2.53
versus 1.70 in authentic), while the average (±SD) ratios
between positions  4 and  26 in aberrant and authentic
30ss were similar (1.52 ± 0.34 and 1.55 ± 0.28, respectively).
Aberrant 30ss with purine at  3 had higher T-to-C ratios
between  11 and  13 than aberrant 30ss with pyrimidine
at  3 (2.54 versus 1.69). The number of Gs in this region
was signiﬁcantly higher in aberrant than authentic 30ss
(153 versus 92 in positions  9t o 12, c
2 ¼ 17.0, P <
0.0001), particularly in cryptic sites, whereas the number of
As in these positions was not different (125 versus 115,
c
2 ¼ 0.4, P ¼ 0.5).
Di-nucleotide composition upstream of aberrant 30ss
The number of AG dinucleotides, which are depleted in ‘AG
exclusion zones’ upstream of authentic 30ss (24,75,84), was
signiﬁcantly higher in aberrant than corresponding authentic
30ss (Supplementary Figure 2B). In a 17 nt sequence
upstream of 30ss where the AG depletion in natural 30ss is
the most pronounced (75), the numbers of authentic and
aberrant 30ss with a non-30ss (‘intervening’) AG were 15
and 36, respectively (c
2 ¼ 8.8, P ¼ 0.003), while the number
of AGs in the two groups was 15 and 40 (binomial test, P ¼
0.0003). The observed frequency of authentic 30ss with non-
30ss AGs in this region ( 16%) was similar to those previ-
ously reported for constitutively (14%) and alternatively
(17%) spliced introns that contained intervening AGs down-
stream of predicted BPS (21). Between positions  3 and
 26, there were 53 versus 80 AG-containing 30ss (c
2 ¼
7.2, P ¼ 0.007) and 64 versus 95 intervening AGs (binomial
test, P ¼ 0.003), respectively. No AG dinucleotides were
found in positions  10 and  11 of aberrant 30ss. Although
the number of intervening AGs was low, putative differences
of these and other purine dinucleotides between aberrant
Table 5. Discrimination of computational tools between authentic, mutated and cryptic/de novo 30ss
Location of aberrant 30splice sites
Exon Intron Both
Mutation in
30YAG (cryptic)
Mutation outside
30YAG (‘de novo’)
Mutation in
30YAG (cryptic)
Mutation outside
30YAG (‘de novo’)
All mutations
Shapiro and Senapathy matrix score
A–M 7.2 · 10
 26 0.4 1.3 · 10
 9 0.16 2.1 · 10
 23
CR–M 5.2 · 10
 8 0.5 4.1 · 10
 7 0.09 2.9 · 10
 5
A–CR 1.2 · 10
 13 0.4 0.13 0.01 9.5 · 10
 11
Maximum entropy model
A–M 2.4 · 10
 28 0.3 1.6 · 10
 10 8.4 · 10
 9 <10
 32
CR–M 1.3 · 10
 11 0.4 2.2 · 10
 8 8.4 · 10
 3 6.9 · 10
 13
A–CR 1.5 · 10
 15 0.2 4.5 · 10
 3 1.9 · 10
 3 1.8 · 10
 15
First-order Markov model
A–M 2.3 · 10
 28 0.3 1.2 · 10
 10 1.5 · 10
 8 <10
 32
CR–M 1.0 · 10
 11 0.2 5.2 · 10
 9 9.3 · 10
 3 1.7 · 10
 12
A–CR 5.1 · 10
 16 0.1 0.01 6.3 · 10
 3 1.4 · 10
 14
Weight matrix model
A–M 1.9 · 10
 24 0.4 4.1 · 10
 10 0.09 2.5 · 10
 24
CR–M 3.2 · 10
 7 0.2 1.4 · 10
 8 0.4 8.1 · 10
 6
A–CR 2.7 · 10
 13 0.2 0.04 0.07 1.8 · 10
 10
Information contents
A–M 9.2 · 10
 23 0.3 4.8 · 10
 9 0.08 1.9 · 10
 20
CR–M 1.8 · 10
 10 0.3 2.9 · 10
 7 0.2 5.7 · 10
 9
A–CR 6.8 · 10
 11 0.2 0.02 0.2 3.2 · 10
 9
Table cells contain P-values of Wilcoxon Mann–Whitney rank tests comparing authentic (A), mutated (M) and cryptic/de novo (CR) 30ss. P-values < 0.05 are
in bold.
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upstream of 30ss are consistent with a distinct average dis-
tance of the BPS from aberrant versus authentic 30ss. Peak
frequencies of the GA and AA dinucleotides that may signify
the presence of branchpoint in the mammalian BPS con-
sensus YNYURAY were shifted several nucleotides upstream
in aberrant 30ss (Supplementary Figure 2B).
The remaining purine dinucleotides were also more com-
mon in aberrant than in authentic sites. The increase of AA
dinucleotides (253 versus 185 in positions  26 to  3, P ¼
0.001), which were found in excess upstream of authentic
30ss as compared to pseudo-sites (75), was largely attributable
to position  3 due to the excess of  3As in aberrant 30ss
(Supplementary Figure 2A, B). The GG dinucleotides
(186 in aberrant versus 118 in authentic sites in the same
region, P < 0.0001) also clustered in some positions, such
as  17 to  21 (56 versus 19, c
2 ¼ 17.9, P < 0.0001) and
 8t o 12 (49 versus 26, c
2 ¼ 6.7, P < 0.01, respectively).
A region upstream of 30ss in vertebrates (75) and
Arabidopsis thaliana (85) contains a higher number of TG
dinucleotides as compared to pseudo-splice sites, suggesting
that they are important for correct 30ss recognition. Although
the total number of TGs in positions  3t o 26 was similar
in aberrant and authentic 30ss (430 versus 428), there were
94 and 60 TGs in positions  10 to  13 in aberrant and
corresponding authentic sites, respectively (c
2 ¼ 7.7,
P ¼ 0.005). The number of GTs in the same region was
also higher in aberrant sites (56 versus 34; c
2 ¼ 5.2, P ¼
0.02). In contrast, the number of TTs in the same region
was similar (235 versus 200, P > 0.05) both in cryptic and
de novo sites, whereas aberrant 30ss showed TT depletion
for most of the remaining positions. The number of CC
dinucleotides between position  10 and  13 was lower in
aberrant 30ss (71 versus 99, c
2 ¼ 4.7, P ¼ 0.03), but this dif-
ference was limited to de novo sites (c
2 ¼ 10.7, P ¼ 0.001).
The TT-to-CC ratio in aberrant 30ss was the highest in posi-
tion  12 (8.14 versus 2.76 in authentic), whereas the average
(±SD) between positions  5t o 26 was 2.26 (±1.43), with
2.21 ± 0.56 in authentic counterparts.
Position  11 shows peak uridine frequencies in vertebrate
PPTs (86), most probably due to highly conserved interac-
tions with the second RNA recognition motif (RRM2) of
U2AF65, a central organizing force for 30ss recognition in
higher eukaryotes, or with competing pyrimidine-binding
proteins (14,87,88). The same position was efﬁciently cross-
linked to RRM2 of U2AF65 in several PPTs (87) and substi-
tutions of T 11 generated lower levels of spliced products
and prespliceosomal complexes than identical mutations of
T 8 or T 14 (89), suggesting that the observed single- and
di-nucleotide imbalances between aberrant and authentic
30ss centred around this position have functional signiﬁcance.
Higher T-to-C and TT-to-CC ratios in aberrant 30ss in this
area are proposed to improve these interactions and function-
ally compensate their less favourable sequence context (Sup-
plementary Figure 2A and Tables 4 and 5). The difference
in the number of C 12C 11 between aberrant and authentic
30ss (7 versus 21, c
2 ¼ 6.4, P ¼ 0.01) suggests that this
di-nucleotide does not sufﬁciently promote U2AF binding
and that at least one uridine is required in either position
for the productive interaction since the numbers of
T 12C 11 or C 12T 11 were not signiﬁcantly different in
aberrant and authentic 30ss (Supplementary Figure 2B).
This notion is in agreement with  80- to 100-fold inhibition
of U2AF65 binding following chemical modiﬁcation of
the uridine N3 and O4 atoms, the only positions that differ
between the two nucleosides (90). However, the CC dinuc-
leotides in positions  11 to  13 were over-represented
in authentic counterparts of de novo sites (53 versus 21,
c
2 ¼ 13.7, P < 0.001) but not cryptic sites (19 versus 26,
P > 0.05), suggesting that they signify natural 30ss that
compete poorly with and may be susceptible to mutation-
induced 30ss.
In contrast to cytosines, both de novo and cryptic 30ss
showed an increase of TGs/GTs between positions  10 and
 13 (64 versus 40, c
2 ¼ 5.4, P < 0.05 and 86 versus 54,
c
2 ¼ 7.4, P < 0.01, respectively) as compared to authentic
counterparts. A relative lack of G 12T 11/T 11G 10 in
authentic sites suggests that such 30ss may compete relatively
well with newly introduced 30ss, consistent with an earlier
observation that GU tracts can substitute for pyrimidine tracts
(91), probably as a result of ﬂexible side chain rearrange-
ments of U2AF65 and/or relocation of bound water
molecules (92).
Depletion of aberrant 30ss upstream and downstream of
authentic 30ss
Distribution of the distances between aberrant and authentic
30ss with the updated sample conﬁrmed a previously reported
(11) bias of cryptic 30ss towards exons and de novo sites
towards introns (Supplementary Figure 3A and B). Major fre-
quency peaks for cryptic and de novo 30ss were 8 and  10 nt
from authentic 30ss, respectively (median distances in each
category of aberrant 30ss are in Table 1). In addition, a relat-
ive depletion of both in cryptic and de novo 30ss emerged
further upstream and downstream. A lack of cryptic 30ss
upstream is apparently due to AG depletion (11), although
cryptic 30ss activation may also be prevented by spliceosomal
complexes assembled around the branch site. The latter
explanation is likely to account for the observed depletion
of de novo 30ss, which is more upstream as compared to cryp-
tic sites ( 50 nt, Supplementary Figure 3B).
Smaller areas of depletion for cryptic 30ss 30–40 nt down-
stream of authentic 30ss and  20 nt downstream for de novo
sites was followed by a second peak at 50–60 nt. The exonic
depletion may be explained by a lack of suitable alternative
BP adenosines within an optimal distance from de novo
30ss, cross-exon interactions, selection against codons carry-
ing AGs or a combination of these factors. In contrast to
asymmetric distribution of cryptic and de novo 30ss, the fre-
quency plot of all aberrant 30ss was virtually symmetric,
with a median distance of just 1 nt from authentic 30ss
(Table 1 and data not shown). Finally, the observed frequency
distribution suggests that aberrant 30ss retaining the BPS and
PPT of their authentic counterparts may be more frequent
than those that use a new BPS-PPT-30AG unit.
DBASS3: a database of aberrant 30ss
Nucleotide sequences of all aberrant 30ss were compiled in a
new online resource available at http://www.dbass3.soton.ac.
uk/. The DBASS3 web interface provides access to the data-
base through the ‘search’ option. The user can search
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of aberrant 30ss and their distance from authentic 30ss. Aber-
rant 30ss generated in terminal exons can also be easily
retrieved. In cases in which a search identiﬁes more than
one database entry, the results page displays the gene, pheno-
type and location of aberrant 30ss for all corresponding hits.
The user can then choose details pages that show nucleotide
sequences ﬂanking the authentic and cryptic 30ss, literature
references with PubMed links and the estimated strength of
each splice site for the tested algorithms. In addition, the
details page shows how aberrant 30ss change the reading
frame of each transcript (0, +1 and +2 nt). DBASS3 visitors
can also submit published data to the corresponding author
and receive regular updates by email. Potential applications
of DBASS3 include the optimization of computational tools
for prediction of aberrant splice sites, detection of introns
or exons that are frequently involved in aberrant splicing,
identiﬁcation of splicing mutations and aberrant 30ss in a
gene or phenotype of interest, and investigating basic mech-
anisms of 30ss selection.
DISCUSSION
A high proportion of AG-creating mutations activating
aberrant 30ss
This study is the ﬁrst to provide a detailed survey of muta-
tions leading to aberrant 30ss. It showed that the distribution
of single-nucleotide substitutions roughly reﬂected the degree
of conservation of consensus sequences that deﬁne 30ss
(Figure 1) and revealed a high proportion of mutations creat-
ing the 30AG consensus (Table 1). The observed frequency of
AG-creating mutations (42%) was considerably higher than
the estimated  13% in the initial analysis of splicing
mutations (47). Only  5% (n ¼ 11, Table 2) of these muta-
tions failed to activate de novo 30ss in situ and instead
induced one or more aberrant 30ss upstream (36,70,93–96)
or downstream (62,97,98) of the newly introduced AGs.
These mutations were in position  3 (36,93),  9 (62,98),
 10 (96),  14 (70),  15 (97),  17 (95) and  24 (94) relat-
ive to authentic 30ss (Supplementary Table 1). Mutations in
positions  3 and  24 directly inactivated 30YAG and BPS,
respectively, but the remaining AG-creating mutations were
all in ‘AG-exclusion zones’ downstream of the BPS. The
distance between predicted BP adenosine and new 30AG/
was 9–20 nt (Supplementary Table 1). Aberrant 30ss with
the ‘BP-new AG’ distances between 9 and 16 nt were either
in exons or upstream of the BPS, and new AGs were never
selected as 30ss, consistent with protein complexes bound to
 19 nt region downstream of BP (99). In the FALDH gene
(70), this distance was 20 nt and normally silent AG located
9 nt downstream of the BPS was activated by the newly
created AG further 11 nt downstream. However, this putative
exception can be explained by inefﬁcient recognition of new
30AG, which was preceded by G, unlike the remaining aber-
rant 30ss (Supplementary Table 1). Alternatively, selection
of aberrant 30ss in this FALDH intron can be explained by
almost identical BPS sequences arranged in tandem, with
the upstream BP in the optimal distance (18 nt) from aberrant
30ss. In contrast, wild-type AGs 6 and 7 nt downstream of the
predicted BP were not selected (36,98). Although the location
of AG exclusion zones is likely to be substrate-dependent,
these data suggest that the average zone is between  7 and
 19 nt downstream of the BP adenosine, consistent with pre-
vious studies of intervening AGs (11,19,21,99).
Selection of cryptic 30ss upstream of BPS
If 30ss are selected by unidirectional scanning for 30YAG
downstream of the BPS (91), why are so many cryptic 30ss
upstream of the predicted BPS used in vivo? Inspection of
downstream exonic sequences in 29 cases of intronic cryptic
30ss (Table 2) showed that eight were in terminal introns
(67,100–106) (Table 1), which was signiﬁcantly more
frequent (c
2 ¼ 5.6, P ¼ 0.018) than for the remaining cat-
egories of aberrant 30ss (Table 1), one was activated in a
downstream intron (107) and two were associated with cryp-
tic 30ss in the following exon (108). Of the remaining sites, 13
cases either completely lacked exonic 30YAG consensus in
the context of four or more upstream pyrimidines or con-
tained this consensus only in the last 20 nt of the exon
(2,65,66,72,93,109–116) These 30YAGs are unlikely to be
used as 30ss given inefﬁcient inclusion of very small exons
in mRNA (117) and a typical recognition site of RRM of
 4–7 nt [(87) and references therein]. This strongly suggests
that the choice of upstream 30ss is inﬂuenced by the availab-
ility of 30YAGs in the downstream exon and their distance
from the exon end, and is consistent with unidirectional scan-
ning that is inefﬁcient in terminal exons. It is therefore pos-
sible that a new, competing BPS-PPT-30AG unit is selected
after the initial scanning of the downstream exon for AGs
is completed. However, there has been no obvious reason
for using upstream 30ss in at least some of the remaining
introns (36,118,119). These rare cases and similar examples
identiﬁed in the future might provide interesting insights
into cellular mechanisms that discriminate between authentic
30ss and pseudo-acceptors.
Random distribution of the reading frames in
transcripts that use aberrant 30ss
Aberrant splicing often results in transcripts containing
premature termination codons (PTCs). Such transcripts are
downregulated by nonsense mediated RNA decay (NMD),
which degrades PTC-containing mRNAs whose translation
may be deleterious for the cell (120). Whereas EST databases
over-represent alternative splicing events that maintain the
reading frame (121), neither cryptic 50ss (10) nor aberrant
30ss (Table 1, c
2 ¼ 8.2, 6 d.f., P ¼ 0.2) (11) showed any
bias against splice sites involving a frameshift with respect
to the authentic sites, even though many mRNAs frameshif-
ted by +1 and +2 nt would be expected to trigger NMD.
These results can be explained by a great reduction of RNA
downregulation in response to a PTC in transcripts containing
PPT Y-to-R mutations that reduced splicing (122). In addi-
tion, NMD usually does not completely eliminate RNAs
with PTCs and the activated cryptic sites that result in frame-
shifts can still be detected with RT–PCR, a method used by
the authors of most DBASS3 records.
The maximum entropy model as a method of choice for
predicting aberrant 30ss
This study demonstrated that the ability of current computa-
tional tools to predict utilization of aberrant 30ss is inﬂuenced
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overall model discriminating authentic and aberrant 30 ss
was the ME model, validating previous predictions based
on comparisons of genuine 30ss and pseudo-acceptors (28).
The ME model outperformed the remaining algorithms for
each category of aberrant 30ss and, together with the MM
model, was the only method that could separate authentic
from de novo 30ss in introns at a signiﬁcance level <0.01.
Since none of the tested tools discriminated between de
novo 30ss in exons and their authentic counterparts
(Table 5), these aberrant 30ss were tested with additional
algorithms, including NetGene2 (25,123) available at http://
genome.cbs.dtu.dk/services/NetGene2/ and ASSP (alternative
splice site predictor; http://es.embnet.org/~mwang/assp.html)
method (124). NetGene2 considers more distant features that
include global coding information and distances between
potential splice sites, whereas ASSP is based on two neural
networks pre-processed by position speciﬁc matrix scores.
However, neither method revealed a difference for this
category of aberrant 30ss.
Although this study is the ﬁrst to focus on 30ss utilized
in vivo as opposed to previous comparisons with pseudo-
sites, there are limitations of this approach. First, even though
each aberrant 30ss was conﬁrmed by sequencing, aberrant
splicing was reliably and accurately quantiﬁed only in a sub-
set of case reports and was highly variable from mutation to
mutation, ranging from a few to hundred per cent utilization.
This could be improved in future case reports and, as
DBASS3 submissions permit inclusion of this information
in future database records, taken into account in subsequent
analyses. Second, despite the cell-speciﬁc nature of alternat-
ive splicing, measurements of aberrant and authentic RNA
products have been obtained largely for blood leukocytes
and only rarely for other cell types. Even with these limita-
tions, future updates of DBASS3 may provide valuable
insights into nucleotide dependencies between individual
positions and distribution of trinucleotides that were signiﬁc-
antly favoured or avoided upstream of authentic 30ss as com-
pared to pseudo-sites (75), as well as other motifs.
CONCLUSIONS
This work showed that (i) almost one half of aberrant 30ss
resulted from AG-creating mutations and from the introduc-
tion of guanosine, a virtually invariant nucleotide in both
terminal positions of U2-dependent introns; (ii) the higher
frequency of transitions over transversions observed
for both positions of 30AG can be attributed to relative
di-nucleotide mutability rates rather than a detection bias res-
ulting from a differential splicing efﬁciency of mutated
30AGs; (iii) purine transitions leading to de novo sites in
introns were more frequent than for de novo sites in exons;
(iv) the maximum entropy model was the best model discrim-
inating authentic and mutation-induced aberrant 30ss used
in vivo; (v) authentic counterparts of de novo 30ss were
intrinsically weak; (vi) the nucleotide sequence upstream of
aberrant 30ss had a higher purine content than corresponding
authentic sites, particularly in position  3; (vii) as with
authentic sites, aberrant 30ss showed positive associations at
 3 with upstream positions that may result from functional
compensation of weaker interactions of U2AF with 30TAG
by stronger interactions with PPT uridines around position
 11 and with more optimal BPS; (viii) the extreme rarity
of AGs between positions  6 and  15 in authentic 30ss
(75,84) was violated in aberrant 30ss, particularly 5–9 nt
upstream of new intron/exon junctions; (ix) although uridines
were generally under-represented upstream of aberrant 30ss,
they maintained their high numbers at position  11 and
ﬂanking nt for predicted interaction with U2AF65 or other
PPT-binding proteins; (x) in this region, aberrant 30ss had
higher T-to-C and TT-to-CC ratios, required a complete
lack of AGs, but tolerated more guanosines and UG/GU
dinucleotides than authentic sites. Finally, the development
and maintenance of DBASS3 will facilitate prediction of
cryptic or de novo 30ss in mutated disease genes, identiﬁca-
tion of introns or exons that are frequently involved in aber-
rant splicing, structural dissection of interactions leading to
selection of 30ss in vivo, and reﬁnement of computational
methods that estimate the splice site strength.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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